@article{c6d853285514465ba09ff138bd8c36f8,
title = "The tumor suppressor protein p53 and the ferroptosis network",
abstract = "Ferroptosis is a form of lipid peroxidation-induced cell death that can be regulated in many ways, from altering the activity of antioxidant enzymes to the level of transcription factors. The p53 tumor suppressor is {\textquoteleft}the guardian of the genome{\textquoteright} that participates in the control of cell survival and division under various stresses. Beyond its effects on apoptosis, autophagy, and cell cycle, p53 also regulates ferroptosis either through a transcriptional or posttranslational mechanism. On one hand, p53 can enhance ferroptosis by inhibiting the expression of SLC7A11 (solute carrier family 7 member 11) or by enhancing that of SAT1 (spermidine/spermine N1-acetyltransferase 1) and GLS2 (glutaminase 2). On the other hand, p53 suppresses ferroptosis through the direct inhibition of DPP4 (dipeptidyl peptidase 4) activity or by the induction of CDKN1A/p21 (cyclin dependent kinase inhibitor 1 A) expression. Here, we review recent discoveries and emerging trends in the study of the ferroptosis network and highlight the context-dependent impact of p53 on ferroptosis and oxidative stress.",
keywords = "Autophagy, Cell death, Ferroptosis, p53",
author = "Rui Kang and Guido Kroemer and Daolin Tang",
note = "Funding Information: We apologize to the researchers who were not referenced due to space limitations. We thank Christine Heiner (Department of Surgery, University of Pittsburgh) for her critical reading of the manuscript. This work was supported by grants from the US National Institutes of Health ( R01GM115366 , R01CA160417 , and R01CA211070 ), the American Cancer Society (Research Scholar Grant RSG-16-014-01-CDD ), the Natural Science Foundation of Guangdong Province ( 2016A030308011 ), the National Natural Science Foundation of China ( 31671435 and 81772508 ), Guangdong Province Universities and Colleges Pearl River Scholar Funded Scheme ( 2017 ), Lin He{\textquoteright}s Academician Workstation of New Medicine and Clinical Translation ( 2017 ), and the International Scientific and Technology Cooperation Program of China ( 2015DFA31490 ). GK is supported by the Ligue contre le Cancer Comit{\'e} de Charente-Maritime ({\'e}quipe labelis{\'e}e) ; Agence National de la Recherche (ANR) – Projets blancs; ANR under the frame of E-Rare-2, the ERA-Net for Research on Rare Diseases; Association pour la recherche sur le cancer (ARC); Canc{\'e}rop{\^o}le Ile-de-France ; Chancelerie des universit{\'e}s de Paris (Legs Poix), Fondation pour la Recherche M{\'e}dicale (FRM); the European Commission (ArtForce); the European Research Council (ERC); Fondation Carrefour ; Institut National du Cancer (INCa); Inserm (HTE); Institut Universitaire de France ; LeDucq Foundation ; the LabEx Immuno-Oncology ; the RHU Torino Lumi{\`e}re, the Searave Foundation ; the SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE); the SIRIC Cancer Research and Personalized Medicine (CARPEM); and the Paris Alliance of Cancer Research Institutes (PACRI). Funding Information: We apologize to the researchers who were not referenced due to space limitations. We thank Christine Heiner (Department of Surgery, University of Pittsburgh) for her critical reading of the manuscript. This work was supported by grants from the US National Institutes of Health (R01GM115366, R01CA160417, and R01CA211070), the American Cancer Society (Research Scholar Grant RSG-16-014-01-CDD), the Natural Science Foundation of Guangdong Province (2016A030308011), the National Natural Science Foundation of China (31671435 and 81772508), Guangdong Province Universities and Colleges Pearl River Scholar Funded Scheme (2017), Lin He's Academician Workstation of New Medicine and Clinical Translation (2017), and the International Scientific and Technology Cooperation Program of China (2015DFA31490). GK is supported by the Ligue contre le Cancer Comit? de Charente-Maritime (?quipe labelis?e); Agence National de la Recherche (ANR) ? Projets blancs; ANR under the frame of E-Rare-2, the ERA-Net for Research on Rare Diseases; Association pour la recherche sur le cancer (ARC); Canc?rop?le Ile-de-France; Chancelerie des universit?s de Paris (Legs Poix), Fondation pour la Recherche M?dicale (FRM); the European Commission (ArtForce); the European Research Council (ERC); Fondation Carrefour; Institut National du Cancer (INCa); Inserm (HTE); Institut Universitaire de France; LeDucq Foundation; the LabEx Immuno-Oncology; the RHU Torino Lumi?re, the Searave Foundation; the SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE); the SIRIC Cancer Research and Personalized Medicine (CARPEM); and the Paris Alliance of Cancer Research Institutes (PACRI). Funding Information: We apologize to the researchers who were not referenced due to space limitations. We thank Christine Heiner (Department of Surgery, University of Pittsburgh) for her critical reading of the manuscript. This work was supported by grants from the US National Institutes of Health (R01GM115366, R01CA160417, and R01CA211070), the American Cancer Society (Research Scholar Grant RSG-16-014-01-CDD), the Natural Science Foundation of Guangdong Province (2016A030308011), the National Natural Science Foundation of China (31671435 and 81772508), Guangdong Province Universities and Colleges Pearl River Scholar Funded Scheme (2017), Lin He's Academician Workstation of New Medicine and Clinical Translation (2017), and the International Scientific and Technology Cooperation Program of China (2015DFA31490). GK is supported by the Ligue contre le Cancer Comit{\'e} de Charente-Maritime ({\'e}quipe labelis{\'e}e); Agence National de la Recherche (ANR) – Projets blancs; ANR under the frame of E-Rare-2, the ERA-Net for Research on Rare Diseases; Association pour la recherche sur le cancer (ARC); Canc{\'e}rop{\^o}le Ile-de-France; Chancelerie des universit{\'e}s de Paris (Legs Poix), Fondation pour la Recherche M{\'e}dicale (FRM); the European Commission (ArtForce); the European Research Council (ERC); Fondation Carrefour; Institut National du Cancer (INCa); Inserm (HTE); Institut Universitaire de France; LeDucq Foundation; the LabEx Immuno-Oncology; the RHU Torino Lumi{\`e}re, the Searave Foundation; the SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE); the SIRIC Cancer Research and Personalized Medicine (CARPEM); and the Paris Alliance of Cancer Research Institutes (PACRI). Publisher Copyright: {\textcopyright} 2018 Elsevier Inc.",
year = "2019",
month = mar,
doi = "10.1016/j.freeradbiomed.2018.05.074",
language = "English (US)",
volume = "133",
pages = "162--168",
journal = "Free Radical Biology and Medicine",
issn = "0891-5849",
publisher = "Elsevier Inc.",
}